The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults ...

The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

The US Food and Drug Administration has approved insulin icodec (Awiqli), developed by Novo Nordisk, as the first once-weekly long-acting basal insulin for glycemic control in adults with Type ...

FDA approves 1st weekly basal insulin, Awiqli, offering adults with Type 2 diabetes a once-weekly injection to improve ...

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly alternative.

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Tirzepatide vs. semaglutide, which is better? Medical experts agree that tirzepatide has better results, but the right drug ...

Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.

March 26 (Reuters) - The U.S. Food and Drug Administration has approved Novo Nordisk's insulin injection, Awiqli, to control ...

BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient ...